Docoh
Loading...

34 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
2B ulcerative Necrobiosis Lipoidica (NL) trial. NL is a rare, chronic, idiopathic, granulomatous disease that can significantly effect a patient’s
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
targeted Necrobiosis Lipoidica (NL) as our lead indication for PCS499. NL is a chronic, disfiguring condition affecting the skin and tissue under … selectivity have been shown to successfully treat gastrointestinal (GI) motility disorders such as gastroparesis, chronic constipation, constipation
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
for PCS499. NL is a chronic, disfiguring condition affecting the skin and tissue under the skin typically on the lower extremities with no currently … shown to successfully treat gastrointestinal (GI) motility disorders such as gastroparesis, chronic constipation, constipation-predominant irritable bowel
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and providing evidence of its safety. “NL” means Necrobiosis Lipoidica, a rare chronic, and granulomatous disorder. “Osteonecrosis” means the death … Necrobiosis Lipoidica (NL) as our lead indication for PCS499. NL is a chronic, disfiguring condition affecting the skin and tissue under the skin typically
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
. The lead indication currently under development for PCS499 is Necrobiosis Lipoidica (NL). NL is a chronic, disfiguring condition affecting the skin … agonists with less 5-HT4 selectivity have been shown to successfully treat gastrointestinal (GI) motility disorders such as chronic constipation
424B4
vhay atgik
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
qrtw3ijs0 m581
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
c9c1pzs
16 Sep 20
IPO registration (amended)
8:00pm
8-K
EX-99.1
tb0vqocbhs
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
10-Q
h1vd jsoicf8h2vpf35
5 Aug 20
Quarterly report
3:32pm
S-1/A
soxam7w 3d6j6
17 Jul 20
IPO registration (amended)
5:25pm
10-Q
xt6zi
15 May 20
Quarterly report
1:23pm
8-K
EX-99.1
xh8aso2i z6zjr
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
8-K
EX-99.1
u5i5nptn
17 Mar 20
Processa Pharmaceuticals Announces Results from the Phase 2 Study In Necrobiosis Lipoidica
9:30am
10-K
xdbhhhrmj23c1h569h
5 Mar 20
Annual report
7:00pm
S-1
2n2lwbleu91
13 Dec 19
IPO registration
5:32pm
10-Q
55p25htb44
14 Nov 19
Quarterly report
11:45am
10-Q
vp5voaxa10m
13 Aug 19
Quarterly report
8:00pm
10-K/A
821nocp518mdlq
5 Apr 19
Annual report (amended)
9:40pm
10-K
omad 6ds7zvhgp41
28 Mar 19
Annual report
5:25pm